Palomino Laboratories Inc. (PALX)
Palomino Laboratories Inc. (PALX)
| Cash Flow | 2026-03-31 |
|---|---|
| Net loss | -1,243,430 |
| Stock-based compensation related to employees and non-employees | 155,478 |
| Depreciation expense | 2,763 |
| Prepaids and other assets | -134,587 |
| Accounts payable | 31,470 |
| Accrued expenses and other liabilities | -197,887 |
| Change in operating lease obligations | 551 |
| Net cash (used in) provided by operating activities | -1,116,468 |
| Purchase of property and equipment | 318,336 |
| Net cash used in investing activities | -318,336 |
| Payment of deferred financing costs | 30,000 |
| Net cash (used in) provided by financing activities | -30,000 |
| Net (decrease) increase in cash and cash equivalents | -1,464,804 |
| Cash and cash equivalents at beginning of the period | 8,121,445 |
| Cash and cash equivalents at end of the period | 6,656,641 |